Oxford Biomedica doubles bioprocessing capacity with new facility

13 September 2018

UK-based Oxford BioMedica (LSE:OXB) is fitting out a new 84,000 square foot (7,800 square meter) facility in Oxford with new lab space, warehousing, QC laboratories, and office space.

The new base, which more than doubles the cell and gene therapy firm’s bioprocessing capacity, will support Phase I and II development, and is funded by a March 2018 placing.

Earlier in the year the firm announced a $100 million collaboration and licence agreement with US hemophilia expert Bioverativ (Nasdaq: BIVV), which was subsequently acquired by French pharma major Sanofi (Euronext: SAN).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK